Related Experiment Video
Updated: Mar 1, 2026
Left Lung Orthotopic Transplantation in a Juvenile Porcine Model for ESLP
Published on: February 14, 2022
Pediatric Lung Transplantation
1Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri. sweet@kids.wustl.edu.
Insights
Pediatric lung transplantation offers a viable treatment for children with end-stage lung disease. Innovations in organ availability, patient bridging, and understanding chronic lung allograft dysfunction are key to improving long-term outcomes.
Area of Science:
- Pediatric Pulmonology
- Transplantation Medicine
- Immunology
Background:
- Pediatric lung transplantation is a critical treatment for end-stage lung disease in children.
- Over 100 pediatric lung transplants are performed annually, highlighting its significance.
- Long-term success faces challenges including organ availability and post-transplant complications.
Purpose of the Study:
- To review current challenges and future opportunities in pediatric lung transplantation.
- To highlight areas for innovation to improve patient outcomes.
- To emphasize the need for research into chronic lung allograft dysfunction.
Main Methods:
- Review of current literature and registry data.
- Discussion of emerging technologies and strategies.
- Identification of research priorities in pediatric lung transplantation.
Main Results:
- Ex vivo lung perfusion shows promise for expanding the donor organ pool.
- Extracorporeal support and rehabilitation can bridge critically ill children to transplant.
- Understanding chronic lung allograft dysfunction mechanisms is crucial for developing new therapies.
Conclusions:
- Pediatric lung transplantation is a viable but complex procedure.
- Advancements in organ preservation, patient support, and understanding of rejection are essential.
- Further research into chronic lung allograft dysfunction is paramount for long-term success.
Abstract:
Pediatric lung transplant is a viable option for treatment of end-stage lung disease in children, with > 100 pediatric lung transplants reported to the Registry of the International Society of Heart and Lung Transplantation each year. Long-term success is limited by availability of donor organs, debilitation as a result of chronic disease, impaired mucus clearance resulting from both surgical and pharmacologic interventions, increased risk for infection resulting from immunosuppression, and most importantly late complications, such as chronic lung allograft dysfunction. Opportunities for investigation and innovation remain in all of these domains: (1) Ex vivo lung perfusion is a promising technology with the potential for increasing the lung donor pool, (2) evolving extracorporeal support strategies coupled with effective rehabilitation will effectively bridge critically ill patients to transplant, and most importantly, (3) research efforts intended to increase our understanding of the underlying mechanisms of chronic lung allograft dysfunction will ultimately lead to the development of effective therapies to prevent or treat the variety of chronic lung allograft dysfunction presentations.
